Merck’s life science business has been awarded a three-year, $136.7 million contract to stand up a factory for a critical material needed to manufacture rapid COVID-19 point-of-care tests.
Since the beginning of the COVID-19 pandemic, PCR assays have been the gold standard for detecting SARS-CoV-2. Mammoth Biosciences (CA, USA) is developing a CRISPR-based diagnostic workflow that aims ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback